Literature DB >> 27054280

Kill: boosting HIV-specific immune responses.

Lydie Trautmann1.   

Abstract

PURPOSE OF REVIEW: Increasing evidence suggests that purging the latent HIV reservoir in virally suppressed individuals will require both the induction of viral replication from its latent state and the elimination of these reactivated HIV-infected cells ('Shock and Kill' strategy). Boosting potent HIV-specific CD8 T cells is a promising way to achieve an HIV cure. RECENT
FINDINGS: Recent studies provided the rationale for developing immune interventions to increase the numbers, function and location of HIV-specific CD8 T cells to purge HIV reservoirs. Multiple approaches are being evaluated including very early suppression of HIV replication in acute infection, adoptive cell transfer, therapeutic vaccination or use of immunomodulatory molecules. New assays to measure the killing and antiviral function of induced HIV-specific CD8 T cells have been developed to assess the efficacy of these new approaches. The strategies combining HIV reactivation and immunobased therapies to boost HIV-specific CD8 T cells can be tested in in-vivo and in-silico models to accelerate the design of new clinical trials.
SUMMARY: New immunobased strategies are explored to boost HIV-specific CD8 T cells able to purge the HIV-infected cells with the ultimate goal of achieving spontaneous control of viral replication without antiretroviral treatment.

Entities:  

Mesh:

Year:  2016        PMID: 27054280      PMCID: PMC5098478          DOI: 10.1097/COH.0000000000000286

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  106 in total

1.  Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.

Authors:  Meghan K Rothenberger; Brandon F Keele; Stephen W Wietgrefe; Courtney V Fletcher; Gregory J Beilman; Jeffrey G Chipman; Alexander Khoruts; Jacob D Estes; Jodi Anderson; Samuel P Callisto; Thomas E Schmidt; Ann Thorkelson; Cavan Reilly; Katherine Perkey; Thomas G Reimann; Netanya S Utay; Krystelle Nganou Makamdop; Mario Stevenson; Daniel C Douek; Ashley T Haase; Timothy W Schacker
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

2.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

3.  Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous Simian Immunodeficiency Virus-specific CD8(+) T cell clones during acute and chronic infection of rhesus macaques.

Authors:  Diane L Bolton; Jacob T Minang; Matthew T Trivett; Kaimei Song; Jennifer J Tuscher; Yuan Li; Michael Piatak; David O'Connor; Jeffrey D Lifson; Mario Roederer; Claes Ohlen
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

4.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

5.  Timely HAART initiation may pave the way for a better viral control.

Authors:  Paola Paci; Federico Martini; Massimo Bernaschi; Gianpiero D'Offizi; Filippo Castiglione
Journal:  BMC Infect Dis       Date:  2011-03-01       Impact factor: 3.090

6.  Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption.

Authors:  Viktor von Wyl; Sara Gianella; Marek Fischer; Barbara Niederoest; Herbert Kuster; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Andri Rauch; Bernard Hirschel; Pietro Vernazza; Rainer Weber; Beda Joos; Huldrych F Günthard
Journal:  PLoS One       Date:  2011-11-15       Impact factor: 3.240

7.  Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.

Authors:  Kai Deng; Mihaela Pertea; Anthony Rongvaux; Leyao Wang; Christine M Durand; Gabriel Ghiaur; Jun Lai; Holly L McHugh; Haiping Hao; Hao Zhang; Joseph B Margolick; Cagan Gurer; Andrew J Murphy; David M Valenzuela; George D Yancopoulos; Steven G Deeks; Till Strowig; Priti Kumar; Janet D Siliciano; Steven L Salzberg; Richard A Flavell; Liang Shan; Robert F Siliciano
Journal:  Nature       Date:  2015-01-07       Impact factor: 49.962

8.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

9.  Short-course antiretroviral therapy in primary HIV infection.

Authors:  Sarah Fidler; Kholoud Porter; Fiona Ewings; John Frater; Gita Ramjee; David Cooper; Helen Rees; Martin Fisher; Mauro Schechter; Pontiano Kaleebu; Giuseppe Tambussi; Sabine Kinloch; Jose M Miro; Anthony Kelleher; Myra McClure; Steve Kaye; Michelle Gabriel; Rodney Phillips; Jonathan Weber; Abdel Babiker
Journal:  N Engl J Med       Date:  2013-01-17       Impact factor: 91.245

Review 10.  Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions.

Authors:  Gina M Graziani; Jonathan B Angel
Journal:  J Int AIDS Soc       Date:  2015-11-09       Impact factor: 5.396

View more
  13 in total

1.  Wake me up before you go: a strategy to reduce the latent HIV reservoir.

Authors:  Nicolas Chomont; Afam A Okoye; David Favre; Lydie Trautmann
Journal:  AIDS       Date:  2018-01-28       Impact factor: 4.177

2.  Small Molecule Targeting of Specific BAF (mSWI/SNF) Complexes for HIV Latency Reversal.

Authors:  Christine A Marian; Mateusz Stoszko; Lili Wang; Matthew W Leighty; Elisa de Crignis; Chad A Maschinot; Jovylyn Gatchalian; Benjamin C Carter; Basudev Chowdhury; Diana C Hargreaves; Jeremy R Duvall; Gerald R Crabtree; Tokameh Mahmoudi; Emily C Dykhuizen
Journal:  Cell Chem Biol       Date:  2018-09-06       Impact factor: 8.116

3.  HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Authors:  Guoxin Wu; Michael Swanson; Aarthi Talla; Donald Graham; Julie Strizki; Daniel Gorman; Richard Jo Barnard; Wade Blair; Ole S Søgaard; Martin Tolstrup; Lars Østergaard; Thomas A Rasmussen; Rafick-Pierre Sekaly; Nancie M Archin; David M Margolis; Daria J Hazuda; Bonnie J Howell
Journal:  JCI Insight       Date:  2017-08-17

4.  Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells.

Authors:  Son Nguyen; Claire Deleage; Samuel Darko; Amy Ransier; Duc P Truong; Divyansh Agarwal; Alberto Sada Japp; Vincent H Wu; Leticia Kuri-Cervantes; Mohamed Abdel-Mohsen; Perla M Del Rio Estrada; Yuria Ablanedo-Terrazas; Emma Gostick; James A Hoxie; Nancy R Zhang; Ali Naji; Gustavo Reyes-Terán; Jacob D Estes; David A Price; Daniel C Douek; Steven G Deeks; Marcus Buggert; Michael R Betts
Journal:  Sci Transl Med       Date:  2019-12-18       Impact factor: 17.956

5.  Delayed differentiation of potent effector CD8+ T cells reducing viremia and reservoir seeding in acute HIV infection.

Authors:  Hiroshi Takata; Supranee Buranapraditkun; Cari Kessing; James L K Fletcher; Roshell Muir; Virginie Tardif; Pearline Cartwright; Claire Vandergeeten; Wendy Bakeman; Carmen N Nichols; Suteeraporn Pinyakorn; Pokrath Hansasuta; Eugene Kroon; Thep Chalermchai; Robert O'Connell; Jerome Kim; Nittaya Phanuphak; Merlin L Robb; Nelson L Michael; Nicolas Chomont; Elias K Haddad; Jintanat Ananworanich; Lydie Trautmann
Journal:  Sci Transl Med       Date:  2017-02-15       Impact factor: 17.956

6.  Modeling HIV-1 Latency Using Primary CD4+ T Cells from Virally Suppressed HIV-1-Infected Individuals on Antiretroviral Therapy.

Authors:  Hiroshi Takata; Cari Kessing; Aaron Sy; Noemia Lima; Julia Sciumbata; Luisa Mori; R Brad Jones; Nicolas Chomont; Nelson L Michael; Susana Valente; Lydie Trautmann
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

7.  Systematic post-mortem analysis of brain tissue from an HIV-1 subtype C viremic decedent revealed a paucity of infection and pathology.

Authors:  Jane Musumali; Peter Julius; Stepfanie N Siyumbwa; Dicle Yalcin; Guobin Kang; Sody Munsaka; John T West; Charles Wood
Journal:  J Neurovirol       Date:  2022-10-05       Impact factor: 3.739

8.  Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.

Authors:  Enrico Richter; Lea Bornemann; Marek Korencak; Galit Alter; Marc Schuster; Stefan Esser; Christoph Boesecke; Juergen Rockstroh; Matthias Gunzer; Hendrik Streeck
Journal:  J Virol       Date:  2022-01-12       Impact factor: 6.549

9.  Role of Tunneling Nanotube-like Structures during the Early Events of HIV Infection: Novel Features of Tissue Compartmentalization and Mechanism of HIV Spread.

Authors:  George Okafo; Silvana Valdebenito; Maribel Donoso; Ross Luu; David Ajasin; Brendan Prideaux; Santhi Gorantla; Eliseo A Eugenin
Journal:  J Immunol       Date:  2020-10-09       Impact factor: 5.422

10.  Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8+ T Cell Responses During Chronic Retroviral Infection.

Authors:  Torben Knuschke; Olga Rotan; Wibke Bayer; Sebastian Kollenda; Julia Dickow; Kathrin Sutter; Wiebke Hansen; Ulf Dittmer; Karl S Lang; Matthias Epple; Jan Buer; Astrid M Westendorf
Journal:  Front Immunol       Date:  2018-04-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.